comparemela.com

Latest Breaking News On - Suresh senan - Page 1 : comparemela.com

Durvalumab Shows Improvements in Overall Survival, Progression-Free Survival for Small Cell Lung Cancer

Both dual primary endpoints progression-free survival and overall survival were met with durvalumab.

Imfinzi Improves Survival, Time to Progression in LS-SCLC

Some patients with limited-stage small cell lung cancer experienced overall survival benefits and progression-free survival via treatment with Imfinzi.

IMFINZI® (durvalumab) significantly improved overall survival and progression-free survival for patients with limited-stage small cell lung cancer in ADRIATIC Phase III trial

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.